Results 171 to 180 of about 27,891 (313)

Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States

ClinicoEconomics and Outcomes Research
Yestle Kim,1 Ni Zeng,2 Jessamine P Winer-Jones,2 Machaon Bonafede,2 Francis Lobo,1 John O’Donnell,1 Taylor Ryan2 1Health Economics and Outcomes Research Madrigal Pharmaceuticals, Inc, West Conshohocken, PA, USA; 2Real World Evidence, Veradigm, Chicago ...
Kim Y, Zeng N, Winer-Jones JP, Bonafede M, Lobo F, O'Donnell J, Ryan T   +6 more
doaj  

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. [PDF]

Sci Prog
Gupta AK, Teasell EM, Economopoulos V, Mirmirani P.   +3 more
europepmc   +1 more source

Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States (SMILE)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world associations between semaglutide 2.4 mg and cardiometabolic comorbidities, biomarkers and cardiovascular risk among adults with overweight or obesity. Methods This retrospective cohort study used US claims data and laboratory measurements from the Komodo Research Database (2016–2024). Adults with obesity or with
Aleksandrina Ruseva, Wojciech Michalak, Matthew Bassan, Ella Xiaoyan Du, Anthony Fabricatore, Bríain Ó Hartaigh, Theo Man, Ramya Ramasubramanian, Pangsibo Shen, Jinlin Song, Zhenxiang Zhao, Francisco Lopez‐Jimenez   +11 more
wiley   +1 more source

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine whether on‐treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large‐scale trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs).
Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji   +5 more
wiley   +1 more source

Kardiológiai vonatkozású diabetológiai újdonságok = Novelties from diabetology with cardiological concerns [PDF]

, 2018
Jermendy, György
core   +1 more source

A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico. [PDF]

Endocrinol Diabetes Metab
González-Gálvez G, Garnica-Cuellar JC, Colín-García MÁ, Ferreira-Hermosillo A, Jiménez-Ramos SA, Contreras-Sandoval AY, Cruz-Puente P, Duarte-Vega M.   +7 more
europepmc   +1 more source

Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass. [PDF]

Biomacromolecules
Castelletto V, de Mello LR, Seitsonen J, Hamley IW.   +3 more
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review. [PDF]

Health Sci Rep
Laraib A, Ahmad U, Laraib SI, Laraib SW, Ali M, Ahmad MH, Hassan M.   +6 more
europepmc   +1 more source